Format

Send to

Choose Destination
Vaccine. 2012 May 30;30 Suppl 2:B26-36. doi: 10.1016/j.vaccine.2011.12.032. Epub 2011 Dec 15.

The changing and dynamic epidemiology of meningococcal disease.

Author information

1
Canadian Center for Vaccinology, Dalhousie University, the IWK Health Centre, and Capital Health, Halifax, Canada. scott.halperin@dal.ca

Abstract

The epidemiology of invasive meningococcal disease continues to change rapidly, even in the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease caused by serogroup C has been achieved in countries that have implemented meningococcal C or quadrivalent meningococcal ACWY conjugate vaccines. Initiation of mass immunization programs with meningococcal A conjugate vaccines across the meningitis belt of Africa may lead to the interruption of cyclical meningococcal epidemics. A meningococcal B vaccination program in New Zealand has led to a decreased incidence of high rates of endemic serogroup B disease. Increases in serogroup Y disease have been observed in certain Nordic countries which, if they persist, may require consideration of use of a multiple serogroup vaccine. The imminent availability of recombinant broadly protective serogroup B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates. Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required.

PMID:
22178525
DOI:
10.1016/j.vaccine.2011.12.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center